Enviomycin

Cyclic Peptide Antibiotic (tuberactinomycin Family)Rx: PrescriptionCompound: Approved

Also known as: Enviomycin sulfate, Tuberactinomycin N, Viomycin N

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Enviomycin (tuberactinomycin N) is a cyclic peptide antibiotic of the tuberactinomycin family, closely related to viomycin. It is used as a second-line antitubercular agent, particularly for multidrug-resistant tuberculosis (MDR-TB). It is administered parenterally and shares cross-resistance with capreomycin and viomycin.

Mechanism of Action

Inhibits bacterial protein synthesis by binding to the 16S rRNA of the 30S ribosomal subunit, interfering with translocation and decoding; also disrupts cell membrane integrity in mycobacteria.

Routes of Administration

IntramuscularIntravenous

Goals & Uses

  • Treatment of multidrug-resistant tuberculosis (MDR-TB)Infectious DiseaseModerate
  • Treatment of drug-susceptible tuberculosisAntimicrobial / AntitubercularLow

Contraindications

  • Pre-existing hearing loss or vestibular dysfunctionAuditory/VestibularModerate
  • Hypersensitivity to enviomycin or tuberactinomycinsAllergicHigh
  • Severe renal impairmentOrganHighKidney function concerns

Adverse Effects

  • Vestibular toxicity (vertigo, ataxia)VestibularUncommon
  • Electrolyte disturbances (hypokalemia, hypomagnesemia)MetabolicUncommon
  • Injection site pain or indurationLocalCommon
  • NephrotoxicityRenalCommon
  • Ototoxicity (hearing loss, tinnitus)AuditoryCommon

Drug Interactions

  • Aminoglycosides (e.g., streptomycin, amikacin)High
  • Neuromuscular blocking agentsModerate
  • CapreomycinHigh
  • Loop diuretics (e.g., furosemide)High

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Patients with pre-existing renal diseaseOrgan DysfunctionRelative

Regulatory Status

  • European UnionUnapprovedNot approved by the EMA; not commercially available in the European Union.
  • United StatesUnapprovedNot approved by the FDA; not available commercially in the US.
  • United KingdomUnapprovedNot approved by MHRA; not commercially available in the UK.

Approved in Japan for use against tuberculosis, including drug-resistant strains. Not approved by the US FDA or EMA as a standalone agent; considered an orphan/niche antibiotic in non-Japanese markets.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack